An Open-Label, Multicentre Study to Evaluate the Duration of Clinical Remission of Two Courses of Weekly Intramuscular administration of AMEVIVE (alefacept) by evaluating the time to retreatment with AMEVIVE or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practice

This is an open-label, multicentre study to evaluate the duration of clinical remission of two courses of weekly intramuscular administration of amevive (alefacept) by evaluating the time to retreatment with amevive or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practice. It may be open to people who are at least 16 years old. Participants generally need to have must have been diagnosed with chronic plaque psoriasis and require systemic therapy.